FDA Approves Adrabetadex as First Therapy Shown to Improve Survival in Infantile-Onset Niemann-Pick Disease Type C

Regulatory Approvals — FDA Approves Adrabetadex as First Therapy Shown to Improve Survival in Infantile-Onset Niemann-Pick Disease Type C  NeurologyLive

Read the original at Regulatory Approvals ↗

Auto-published by the finit.news Events monitor from Regulatory Approvals; summarized by AI and may contain errors — verify against the primary source. November 17, 2026.

By